The class of weight-loss and diabetes drugs, GLP-1s, known as Ozempic, Wegovy, Mounjaro and Zepbound, have been found to have unexpected benefits linked to these drugs, including rapid weight loss and decreased blood pressure and A1C. The anti-inflammatory effects of these drugs have led to decreased inflammation and decreased food cravings. However, there are also risks and benefits associated with the drugs, which also reduce the risk of heart attacks, strokes, and cardiovascular death. South Florida clinicians have seen these surprising benefits firsthand. Dr. Leonard J. Pianko, founder and medical director of the Aventura Cardiovascular Center, lost nearly 90 pounds while taking GLPs-1 medications and is about to switch to the Wegovo pill, which was recently introduced in pharmacies. South Floridians are also seeing improvements in various health conditions such as sleep apnea, joint pain, liver disease, heart disease, asthma, and addiction. The U.S. Food and Drug Administration has approved the Wegivy injection for Wegogy (semaglutide) injection to treat adults with excessive scar tissue in the liver for nonalcoholic fatty liver disease.